VioQuest Competitors

Delisted . USA . 
Stock . VioQuest Pharmaceuticals
VOQPDelisted Stock  USD 0  0.00  0.00%   
VioQuest Pharmaceuticals competes with Orphazyme A/S; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing VioQuest Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of VioQuest Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

VioQuest Pharmaceuticals vs Nanologix Correlation

No risk reduction

The correlation between VioQuest Pharmaceuticals and NNLX is 1.0 (i.e., No risk reduction) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding VioQuest Pharmaceuticals and NNLX in the same portfolio, assuming nothing else is changed.

Moving together with VioQuest Pink Sheet

  1.0HDVTY Henderson InvestmentPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.0000.00
Details
Intrinsic
Valuation
LowRealHigh
0.0000.00
Details

VioQuest Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between VioQuest Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of VioQuest and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of VioQuest Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

PARD
+ 1.0
QBIO
AOLS
+ 1.0
QBIO
RCAR
+ 1.0
QBIO
NNLX
+ 1.0
QBIO
AOLS
+ 1.0
PARD
RCAR
+ 1.0
PARD
  

High negative correlations

SCPS
- 0.3
RGIN
PXMD
- 0.19
RGIN
VAXX
- 0.16
RGIN
NNLX
- 0.0
PXMD
NNLX
- 0.0
VAXX
NNLX
- 0.0
OZYMF

Risk-Adjusted Indicators

There is a big difference between VioQuest Pink Sheet performing well and VioQuest Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze VioQuest Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
RGIN  7.44  1.88  0.00  0.71  0.00 
 0.00 
 0.00 
 0.00 
 216.67 
QBIO  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
PARD  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
SCPS  7.12  1.37  0.00  0.50  0.00 
 0.00 
 50.00 
(33.33)
 83.33 
AOLS  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
RCAR  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
OZYMF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
VAXX  1,818  1,075  12.05 (1.74) 122.29 
(4,884)
 6,775 
(99.00)
 22,299 
PXMD  23.60  6.80  0.00  2.70  0.00 
 0.00 
 0.00 
(66.67)
 375.00 
NNLX  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

VioQuest Pharmaceuticals Competitive Analysis

The better you understand VioQuest Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, VioQuest Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across VioQuest Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
VOQP RGIN QBIO PARD SCPS AOLS RCAR OZYMF VAXX PXMD
 0.00 
 0 
VioQuest
 0.00 
 0.0001 
Regenicin
 0.00 
 0.0001 
QBIO
 0.00 
 0.0001 
Poniard
 50.00 
 0.0006 
Scopus
 0.00 
 0.0001 
Aeolus
 0.00 
 0.0001 
RenovaCare
 0.00 
 90.00 
Orphazyme
 99.42 
 0.0001 
Vaxxinity
 300.00 
 0.0004 
PaxMedica,
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Very steady
Very steady
Out of control
Very steady
Very steady
Very steady
Out of control
Out of control
Market Performance
(90 Days Performance)
Weakest
Fair
Weakest
Weakest
Fair
Weakest
Weakest
Weakest
Strong
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Small
Risky
Risky
Strong
Risky
Low
Fair
Average
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Cautious Hold
Current Ratio
0.42
N/A
0.02
0.76
0.31
1.3
0.74
5.73
5.46
N/A
Net Asset
1.36 M
15.49 K
809.48 K
11.64 M
8.19 M
4.17 M
3.65 M
173.23 M
44.35 M
5.68 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-2.76
N/A
N/A
EBITDA
(6.84 M)
(655.96 K)
(7.68 M)
(13.04 M)
(26.18 M)
(3.85 M)
(4.46 M)
(603.91 M)
(56.05 M)
(16.15 M)
Current Valuation
163.85 K
659.26 K
10.04 M
434.76 K
1.18 M
167.29 K
3.42 M
(1.82 M)
(1.39 M)
388.33 K
Operating Margin
N/A
N/A
-11.95
N/A
N/A
-5.31
N/A
-15.38
N/A
N/A
Price To Book
N/A
N/A
330.46
0.0963
2.42
0.81
5.11
0.48
4.58
1.84
Retained Earnings
(44.35 M)
(11.8 M)
(5.94 M)
(438.94 M)
N/A
(184.68 M)
(10.59 M)
N/A
(361.64 M)
(52.03 M)
Current Asset
1.13 M
293 K
148 K
5.22 M
N/A
4.13 M
700 K
N/A
N/A
N/A
Beta
-0.32
-1.79
2.35
0.9
1.16
-3.96
1.93
0.82
2.4
N/A
Number Of Employees
3
3
3
7
9
4
1
2
57
6
Shares Outstanding
N/A
153.48 M
70.32 M
1.5 M
21.09 M
152.09 M
87.35 M
35.31 M
112.91 M
7.47 M
Cash Flow From Operations
(7.08 M)
(27.29 K)
(4.3 M)
(24.28 M)
(11.42 M)
(3.11 M)
(4.56 M)
(602.57 M)
(57.24 M)
(10.77 M)
Annual Yield
0.0278
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
N/A
629.92 K
3.42 M
1.57 M
2.54 M
N/A
800 K
2.48 M
15.17 M
173.54 K
Return On Equity
N/A
N/A
N/A
-2.1
-15.6
-1.86
-5.69
-4.87
-1.51
-10.47
Z Score
-62.5
N/A
-40.7
-55.1
-9.9
-61.6
16.1
-9.3
N/A
N/A
Return On Asset
-1.25
-37.38
-5.12
-0.46
-4.61
-0.9
-1.04
-1.33
-0.48
-2.56
Book Value Per Share
-1.16
-0.036
-0.22
2.08
-0.26
0.001
-0.017
2.22
0.11
0.46
Number Of Shares Shorted
N/A
N/A
N/A
47.72 K
23.77 K
N/A
N/A
N/A
4.22 M
637.72 K
Current Liabilities
2.69 M
1.83 M
1.28 M
1.62 M
N/A
972 K
118 K
N/A
N/A
N/A
Total Asset
1.36 M
15.49 K
809.48 K
11.64 M
8.19 M
4.17 M
3.65 M
173.23 M
44.35 M
5.68 M
Target Price
15.0
N/A
6.0
1.0
12.0
1.25
N/A
N/A
15.0
3.0
Debt To Equity
N/A
0.34
0.71
0.53
0.61
0.3
1.0
4.28
0.094
0.065
Short Ratio
N/A
N/A
N/A
2.56
0.22
N/A
N/A
N/A
13.97
0.1
Shares Owned By Institutions
N/A
0.018
N/A
N/A
2.15
N/A
N/A
8.13
12.24
1.6
Market Capitalization
163.85 K
214.88 K
1.3 M
29
2.17 M
167.29 K
29.7 M
4.59 M
14.09 M
5.14 M
Price To Earning
N/A
-9.7
-3.19
-0.01
N/A
-2.37
-85.28
N/A
N/A
1.9
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.05
N/A
Price To Sales
0.6
N/A
2.55
N/A
N/A
0.22
N/A
0.15
4604.9
N/A
Net Income
(10.89 M)
(639.26 K)
(8.24 M)
(30.05 M)
(26.95 M)
(3.56 M)
(4.47 M)
(626.54 M)
(56.93 M)
(18.29 M)
Earnings Per Share
-2.24
-0.004
-0.3
-3.79
-1.51
-0.03
-0.065
-2.54
-0.45
-11.0
Shares Owned By Insiders
N/A
18.15
8.07
N/A
50.66
N/A
74.18
1.36
50.9
8.14
Revenue
N/A
N/A
195.6 K
N/A
N/A
2.08 M
N/A
36.19 M
N/A
N/A
Working Capital
(1.56 M)
(1.53 M)
(1.13 M)
3.6 M
N/A
3.16 M
582 K
N/A
15.62 M
3.89 M
Cash And Equivalents
814.48 K
2.24 K
27.17 K
1.98 M
1.16 M
403 K
243.96 K
49.53 M
128.23 M
9.06 K
Cash Per Share
0.17
N/A
N/A
1.32
0.05
N/A
N/A
1.4
1.02
N/A
Gross Profit
N/A
N/A
(51.25 K)
N/A
N/A
(805 K)
N/A
36.19 M
(1.87 M)
N/A
Daily Balance Of Power
0.0
0.0
0.0
0.0
9.2 T
0.0
0.0
0.0
0
9.2 T
Day Typical Price
0.003
1.0E-4
1.0E-4
1.0E-4
6.0E-4
1.0E-4
1.0E-4
90.0
1.0E-4
4.0E-4
Period Momentum Indicator
N/A
N/A
N/A
N/A
2.0E-4
N/A
N/A
N/A
(0.02)
3.0E-4
Rate Of Daily Change
1.0
1.0
1.0
1.0
1.5
1.0
1.0
1.0
0.0058
4.0
Day Median Price
0.003
1.0E-4
1.0E-4
1.0E-4
6.0E-4
1.0E-4
1.0E-4
90.0
1.0E-4
4.0E-4
Price Action Indicator
N/A
N/A
N/A
N/A
1.0E-4
N/A
N/A
N/A
(0.01)
1.0E-4
Coefficient Of Variation
N/A
1116.76
N/A
N/A
906.22
N/A
N/A
N/A
372.72
871.52
Mean Deviation
N/A
7.44
N/A
N/A
7.12
N/A
N/A
N/A
1817.73
23.6
Jensen Alpha
N/A
1.88
N/A
N/A
1.37
N/A
N/A
N/A
1074.64
6.8
Total Risk Alpha
N/A
(0.70)
N/A
N/A
(0.12)
N/A
N/A
N/A
572.0
(0.20)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
12.05
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
7160.67
N/A
Standard Deviation
N/A
24.25
N/A
N/A
15.33
N/A
N/A
N/A
3801.62
61.45
Kurtosis
N/A
25.86
N/A
N/A
5.47
N/A
N/A
N/A
19.21
16.29
Potential Upside
N/A
N/A
N/A
N/A
50.0
N/A
N/A
N/A
6775.0
N/A
Treynor Ratio
N/A
0.7081
N/A
N/A
0.4971
N/A
N/A
N/A
(1.74)
2.7
Maximum Drawdown
N/A
216.67
N/A
N/A
83.33
N/A
N/A
N/A
22299.42
375.0
Variance
N/A
588.2
N/A
N/A
235.08
N/A
N/A
N/A
1.445228396E7
3775.66
Market Risk Adjusted Performance
N/A
0.7181
N/A
N/A
0.5071
N/A
N/A
N/A
(1.73)
2.71
Risk Adjusted Performance
N/A
0.0806
N/A
N/A
0.0969
N/A
N/A
N/A
0.2226
0.1008
Skewness
N/A
4.19
N/A
N/A
1.31
N/A
N/A
N/A
4.33
3.71
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
122.29
N/A
Information Ratio
N/A
0.0853
N/A
N/A
0.1036
N/A
N/A
N/A
0.2683
0.1131
Value At Risk
N/A
N/A
N/A
N/A
(33.33)
N/A
N/A
N/A
(99.00)
(66.67)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(4,884)
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
84.62
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
14955.28
N/A

VioQuest Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of VioQuest Pharmaceuticals Competition

VioQuest Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by VioQuest Pharmaceuticals in relation to its competition. VioQuest Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of VioQuest Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact VioQuest Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to VioQuest Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your VioQuest Pharmaceuticals position

In addition to having VioQuest Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Small Value Funds Thematic Idea Now

Small Value Funds
Small Value Funds Theme
Funds or Etfs that invest in the undervalued stocks of small to mid-sized companies. The Small Value Funds theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Value Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.

Other Consideration for investing in VioQuest Pink Sheet

If you are still planning to invest in VioQuest Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VioQuest Pharmaceuticals' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY